Caption Management’s Pacira BioSciences PCRX Stock Holding History

Caption Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-75,000	Closed	-$1.79M	–	1955
2025 Q2	$1.79M	Buy	+75,000	New	+$1.89M	0.02%	748
2024 Q4	–	Sell	-132,500	Closed	-$1.99M	–	1734
2024 Q3	$1.99M	Buy	132,500 +11,700	+10%	+$200K	0.03%	557
2024 Q2	$3.46M	Buy	120,800 +900	+0.8%	+$25.6K	0.05%	366
2024 Q1	$3.5M	Buy	+119,900	New	+$3.68M	0.05%	385

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caption Management's PCRX Position: Q1 2025 in Review

Caption Management sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 53,844 shares — an estimated $1.01M sold.

Caption Management first reported a position in PCRX in Q3 2020 and held it in 7 quarters. The position peaked at $1.42M in Q1 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

Caption Management reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
Caption Management sold 53,844 Pacira BioSciences shares in Q1 2025, an estimated $1.01M.
Caption Management first reported a position in Pacira BioSciences in Q3 2020 and held it in 7 quarters.
Caption Management's Pacira BioSciences position peaked at $1.42M in Q1 2024.
235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.